Evidence map›Paper›PMID 42080249›Full record

ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2026

Usage and positivity rates of Alzheimer's disease biomarkers in a memory clinic.

Anna Hofmann, Benjamin Saef, William J B Powell, Madeline Paczynski, Maria R Ponisio, Clara Vila-Castelar, Zachary Posey, Inez Y Oh, Mackenzie R Hofford, Melissa Aldinger and 11 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Anna HofmannDepartment of Neurology, Washington University, St. Louis, Missouri, USA.ORCID https://orcid.org/0009-0008-6104-8012
Benjamin SaefDepartment of Neurology, Washington University, St. Louis, Missouri, USA.
William J B PowellInstitute for Informatics, Data Science and Biostatistics, Washington University, St. Louis, Missouri, USA.
Madeline PaczynskiDepartment of Neurology, Washington University, St. Louis, Missouri, USA.
Maria R PonisioMallinckrodt Institute of Radiology, Washington University Medicine, St. Louis, Missouri, USA.
Clara Vila-CastelarDepartment of Neurology, Washington University, St. Louis, Missouri, USA.
Zachary PoseyDepartment of Neurology, Washington University, St. Louis, Missouri, USA.
Inez Y OhInstitute for Informatics, Data Science and Biostatistics, Washington University, St. Louis, Missouri, USA.
Mackenzie R HoffordInstitute for Informatics, Data Science and Biostatistics, Washington University, St. Louis, Missouri, USA.
Melissa AldingerDepartment of Neurology, Washington University, St. Louis, Missouri, USA.
Randall J BatemanDepartment of Neurology, Washington University, St. Louis, Missouri, USA.
Cyrus A RajiMallinckrodt Institute of Radiology, Washington University Medicine, St. Louis, Missouri, USA.
Tammie L S BenzingerMallinckrodt Institute of Radiology, Washington University Medicine, St. Louis, Missouri, USA.
Carlos CruchagaKnight Alzheimer Disease Research Center, Washington University, St. Louis, Missouri, USA.
Alan DowBJC Health, St. Louis, Missouri, USA.
Rachel BuckleyMassachusetts General Research Institute, Harvard Medical School, Charlestown, Massachusetts, USA.
Chengjie XiongDepartment of Neurology, Washington University, St. Louis, Missouri, USA.
John C MorrisDepartment of Neurology, Washington University, St. Louis, Missouri, USA.
B Joy SniderDepartment of Neurology, Washington University, St. Louis, Missouri, USA.
Aditi GuptaInstitute for Informatics, Data Science and Biostatistics, Washington University, St. Louis, Missouri, USA.
Suzanne E SchindlerDepartment of Neurology, Washington University, St. Louis, Missouri, USA.

Funding

Examining the impact of sex and hormones on the progression of autosomal dominant Alzheimer's diseaseR00AG073452 · NIA · WASHINGTON UNIVERSITY · PI Clara Vila Castelar · 2025 to 2026
$479k
NIA NIH HHS R00 AG073452NIA NIH HHS R00AG073452
6 · The paper itself

Abstract

introductionUsage of biomarker tests for Alzheimer's disease pathology and rates of positivity were assessed at the Washington University Memory Diagnostic Center.

methodsPatients who underwent at least one biomarker test for clinical purposes between June 2021 and March 2025 were included (n = 1136). Data were retrospectively extracted from electronic health records.

resultsThe median age was 73.2 years (52% female; 93% White). In total, 455 amyloid positron emission tomography (PET) scans, 505 cerebrospinal fluid tests, and 242 blood tests were performed. The number of biomarker tests increased seven-fold over the past 4 years. The rate of positivity was ≈70% across modalities. Higher rates of biomarker positivity were associated with older age, female sex, and White race; lower rates were associated with hypertension and diabetes. DISCUSSION: Biomarker testing greatly increased following the approval of amyloid-targeting treatments. The overall rate of biomarker positivity was high and varied by demographic factors and medical comorbidities.

Indexed as

Alzheimer DiseaseBiomarkersAgedAged, 80 and overAmyloid beta-PeptidesFemaleHumansMaleMiddle AgedPositron-Emission TomographyRetrospective StudiesAmyloid beta-PeptidesBiomarkersamyloid‐targeting treatmentsbiomarkersracial differencesreal‐world evidencesex differences

Identifiers

PMID42080249
PMCPMC13137296

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.